ReviewApplied psychophysiology and biofeedback2026
Neurocognitive Effects of Neurofeedback: A Systematic Review of the Applicability and Therapeutic Effect in Patients with Schizophrenia Spectrum Disorders, Psychosis or Clinical High Risks for Psychosis.
Review in Applied psychophysiology and biofeedback, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Schizophrenia Spectrum Disorders are complex mental health conditions that significantly impact cognitive function and quality of life. While pharmacological and psychotherapeutic interventions are available, their effectiveness remains limited, particularly for negative symptoms and cognitive impairments. These limitations, alongside drug side effects and adherence difficulties, highlight the need for new treatments. Cognitive remediation strategies like Neurofeedback show promise by harnessing neuroplasticity. This systematic review aims to evaluate the neurocognitive and humoral changes induced by Neurofeedback and its therapeutic effects in patients with schizophrenia spectrum disorders. Our review was conducted following PRISMA guidelines. Databases including EMBASE, ScienceDirect, Scopus, PsycINFO, and MEDLINE were searched for relevant studies: 14 studies, 10 RCTs, and 4 Clinical trials were selected. Inclusion criteria encompassed studies involving patients with schizophrenia spectrum disorders, Neurofeedback interventions, and outcomes related to neurocognitive and humoral changes. The Cochrane Risk-of-Bias Tool for randomized trials (RoB 2) was used to assess the quality of included studies. The reviewed studies suggest that Neurofeedback shows promise in addressing various aspects of schizophrenia spectrum disorders. Improvements were observed in processing speed, social functioning, working memory, and emotional regulation. Several studies reported successful modulation of brain activity in regions associated with auditory hallucinations. Neurofeedback training also led to increased functional connectivity between language networks and the default mode network. Some studies found improvements in brain-derived neurotrophic factor (BDNF) levels, self-efficacy, and clinical symptoms in schizophrenia patients. Future research should focus on personalizing Neurofeedback approaches and exploring their mechanisms of action in the context of schizophrenia pathophysiology.
Indexed as
Identifiers
41712163What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.